We also demonstrate proof-of-principle that these fluorescent ligands could be used to screen for hits against the apelin receptor in drug discovery pipelines to identify new compounds that may have clinical use in cardiovascular diseases such as PAH. Here, APLNR is linked to cardiovascular disorder.